FDA slams In­cyte's PD-1 over sin­gle-arm study, low re­sponse and tri­al deaths

The ever-grow­ing PD-1 land­scape could see a new en­trant as an In­cyte pro­gram is slat­ed for an FDA de­ci­sion next month. But first, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.